A new HIV vaccine therapy method lets five patients kick the daily drugs

hiv vaccine therapy daily drugs color
HIV can currently be managed effectively so long as patients conform to a regime of regular antiretrovirals (ARVs). The treatment means that people with HIV can live a normal duration of life so long as they take daily drugs, although if they stop doing so the viral level rapidly increases and starts once again attacking their immune system.

However, a new piece of research suggests that this may not always have to be the case. In fact, the vaccine-based therapy currently being trialed among 13 HIV-active participants resulted in five patients being able to keep a retain a low, non-dangerous viral load — despite one of them not having taken ARVs for 27 weeks. The others were virus free for five, 13, 17, and 20 weeks after stopping taking their regularly scheduled medication.

“It is a proof of concept that with vaccines we might be able to re-educate our immune system to help control the virus once we interrupt treatment,” Beatriz Mothe, a clinician at IrsiCaixa AIDS Research Institute in Barcelona, Spain, told Digital Trends. “It is still a small effect, as only five individuals out of the 13 that have interrupted to date show durable control. But still, it is a positive signal to start deciphering the mechanisms that can drive this control, and test how to improve it in future larger studies.”

This is far from a magic cure-all and it doesn’t claim to be. During the study, eight out of the 13 participants had to restart ARVs, while each of the remaining five had the virus temporarily detectable in their body, although never at sufficient levels to restart the daily drugs.

As Mothe notes, this is still early days. There is a long way to go, she said, to improve its efficacy in larger studies with novel vaccines and novel agents. Still, given the devastation that HIV can cause — and, in parts of the world ravaged by AIDS, the challenge of keeping people compliant with daily ARVs — this is a reason to be optimistic.

The findings were recently presented at the Conference on Retroviruses and Opportunistic Infections, the largest conference on HIV/AIDS in the world.

Product Review

The Asus ZenBook 14 is a tiny notebook that gets lost in the crowd

The ZenBook 14 aims to be the smallest 14-inch notebook around, and it succeeds thanks to some tiny bezels. Performance and battery life are good, but the notebook lacks a standout feature other than size.
Emerging Tech

CRISPR gene therapy regulates hunger, staves off severe obesity in mice

Researchers from UC San Francisco have demonstrated how CRISPR gene editing can be used to prevent severe obesity in mice, without making a single edit to the mouse's genome. Here's how.
Mobile

5G’s arrival is transforming tech. Here’s everything you need to know to keep up

It has been years in the making, but 5G is finally becoming a reality. While 5G coverage is still extremely limited, expect to see it expand in 2019. Not sure what 5G even is? Here's everything you need to know.
Product Review

The 2019 Porsche Macan S is a luxurious and quick SUV, but it's no road tripper

The roster of models challenging the Porsche Macan grows annually. The German firm updated its smallest, most affordable SUV with a new engine, more tech features, and subtle design tweaks to keep it looking fresh.
Smart Home

This A.I.-enabled tech brings cutting-edge automation to grocery stores

Takeoff Technologies is working to make grocery deliveries fast, accurate, and convenient using A.I.-enabled technology to augment robotic grocery orders that can be completed in minutes.
Product Review

This was 3D printed? With the Anycubic Photon, you can't tell

Never mind the fact that the Anycubic Photon 3D printer only costs 500 bucks. In terms of sheer print quality, this printer is on the same level as machines that cost six times as much.
Emerging Tech

Postmates’ to roll out Minion-like autonomous delivery robots in 2019

Postmates is about to employ a cute little robot to work alongside its human delivery personnel. Called Serve, the wheel-based bot can carry items weighing up to 50 pounds and has a range of 30 miles.
Emerging Tech

The best 3D printers of 2018

On the hunt for a new 3D printer? We've got your back. Whether you're a beginner or a seasoned veteran, this list of the best 3D printers has what you're looking for.
Emerging Tech

The best drone photos from around the world

Most of today's drones come equipped with high-end cameras, which are quickly revolutionizing the world of aerial photography as we know it. Here are some of the best drone photos from around the world.
Emerging Tech

Are e-cigarettes safe? Here’s what the most recent science says

Ecigarettes are widely regarded and advertised as a healthier alternative to cigarettes for people who are trying to kick the smoking habit. How safe are these cigarette alternatives? We went deep into the recent scientific literature to…
Emerging Tech

Thrill-seekers will be able to pilot themselves in a giant drone as soon as 2019

Want to hitch a ride on a giant drone? The startup Lift Aircraft is gearing up to let paying customers fly its 18-rotor giant drones over assorted scenic landscapes across the U.S.
Emerging Tech

Capture app saves money by 3D scanning objects using iPhone’s TrueDepth camera

Capture is a new iPhone app created by the Y Combinator-backed startup Standard Cyborg. It allows anyone to perform 3D scans of objects and share them with buddies. Here's how it works.
Emerging Tech

Sick of walking everywhere? Here are the best electric skateboards you can buy

Thanks for Kickstarter and Indiegogo, electric skateboards are carving a bigger niche than you might think. Whether you're into speed, mileage, or something a bit more stylish, here are the best electric skateboards on the market.
Emerging Tech

Rise of the Machines: Here’s how much robots and A.I. progressed in 2018

2018 has generated no shortage of news, and the worlds of A.I. and robotics are no exception. Here are our picks for the most exciting, game changing examples of both we saw this year.